[	0	1	O
Prognostic	1	11	O
significance	12	24	O
of	25	27	O
cellular	28	36	O
vascular	37	45	B-Gene_or_gene_product
endothelial	46	57	I-Gene_or_gene_product
growth	58	64	I-Gene_or_gene_product
factor	65	71	I-Gene_or_gene_product
(	72	73	O
VEGF	73	77	B-Gene_or_gene_product
)	77	78	O
expression	79	89	O
in	90	92	O
the	93	96	O
course	97	103	O
of	104	106	O
chronic	107	114	O
myeloid	115	122	O
leukaemia	123	132	O
]	132	133	O

INTRODUCTION	135	147	O
:	147	148	O
Increased	149	158	O
angiogenesis	159	171	O
in	172	174	O
bone	175	179	B-Multi-tissue_structure
marrow	180	186	I-Multi-tissue_structure
is	187	189	O
one	190	193	O
of	194	196	O
the	197	200	O
characteristics	201	216	O
of	217	219	O
chronic	220	227	O
myeloid	228	235	O
leukaemia	236	245	O
(	246	247	O
CML	247	250	O
)	250	251	O
,	251	252	O
a	253	254	O
clonal	255	261	O
myeloproliferative	262	280	O
disorder	281	289	O
that	290	294	O
expresses	295	304	O
a	305	306	O
chimeric	307	315	O
bcr	316	319	B-Gene_or_gene_product
/	319	320	O
abl	320	323	B-Gene_or_gene_product
protein	324	331	O
.	331	332	O

Vascular	333	341	B-Gene_or_gene_product
endothelial	342	353	I-Gene_or_gene_product
growth	354	360	I-Gene_or_gene_product
factor	361	367	I-Gene_or_gene_product
(	368	369	O
VEGF	369	373	B-Gene_or_gene_product
)	373	374	O
is	375	377	O
one	378	381	O
of	382	384	O
the	385	388	O
most	389	393	O
potent	394	400	O
and	401	404	O
a	405	406	O
specific	407	415	O
regulator	416	425	O
of	426	428	O
angiogenesis	429	441	O
which	442	447	O
principally	448	459	O
targets	460	467	O
endothelial	468	479	B-Cell
cells	480	485	I-Cell
and	486	489	O
regulates	490	499	O
several	500	507	O
of	508	510	O
their	511	516	O
functions	517	526	O
,	526	527	O
including	528	537	O
mitogenesis	538	549	O
,	549	550	O
permeability	551	563	O
and	564	567	O
migration	568	577	O
.	577	578	O

The	579	582	O
impact	583	589	O
of	590	592	O
elevated	593	601	O
VEGF	602	606	B-Gene_or_gene_product
expression	607	617	O
on	618	620	O
the	621	624	O
course	625	631	O
of	632	634	O
chronic	635	642	O
myeloid	643	650	O
leukaemia	651	660	O
is	661	663	O
unknown	664	671	O
.	671	672	O

OBJECTIVE	673	682	O
:	682	683	O
The	684	687	O
aim	688	691	O
of	692	694	O
this	695	699	O
study	700	705	O
was	706	709	O
the	710	713	O
follow	714	720	O
-	720	721	O
up	721	723	O
of	724	726	O
VEGF	727	731	B-Gene_or_gene_product
expression	732	742	O
during	743	749	O
the	750	753	O
course	754	760	O
of	761	763	O
CML	764	767	O
.	767	768	O

METHODS	769	776	O
:	776	777	O
We	778	780	O
studied	781	788	O
VEGF	789	793	B-Gene_or_gene_product
expression	794	804	O
of	805	807	O
85	808	810	O
CML	811	814	O
patients	815	823	B-Organism
(	824	825	O
median	825	831	O
age	832	835	O
50	836	838	O
years	839	844	O
,	844	845	O
range	846	851	O
16	852	854	O
-	854	855	O
75	855	857	O
years	858	863	O
)	863	864	O
.	864	865	O

At	866	868	O
the	869	872	O
commencement	873	885	O
of	886	888	O
the	889	892	O
study	893	898	O
,	898	899	O
29	900	902	O
patients	903	911	B-Organism
were	912	916	O
in	917	919	O
chronic	920	927	O
phase	928	933	O
(	934	935	O
CP	935	937	O
)	937	938	O
,	938	939	O
25	940	942	O
in	943	945	O
an	946	948	O
accelerated	949	960	O
phase	961	966	O
(	967	968	O
AP	968	970	O
)	970	971	O
,	971	972	O
and	973	976	O
31	977	979	O
in	980	982	O
the	983	986	O
blast	987	992	O
crisis	993	999	O
(	1000	1001	O
BC	1001	1003	O
)	1003	1004	O
.	1004	1005	O

The	1006	1009	O
temporal	1010	1018	O
expression	1019	1029	O
(	1030	1031	O
percentage	1031	1041	O
positivity	1042	1052	O
per	1053	1056	O
1000	1057	1061	O
analysed	1062	1070	O
cells	1071	1076	B-Cell
)	1076	1077	O
VEGF	1078	1082	B-Gene_or_gene_product
proteins	1083	1091	O
over	1092	1096	O
the	1097	1100	O
course	1101	1107	O
of	1108	1110	O
CML	1111	1114	O
were	1115	1119	O
studied	1120	1127	O
using	1128	1133	O
the	1134	1137	O
immunohistochemical	1138	1157	O
technique	1158	1167	O
utilizing	1168	1177	O
relevant	1178	1186	O
monoclonal	1187	1197	O
antibodies	1198	1208	O
.	1208	1209	O

It	1210	1212	O
was	1213	1216	O
correlated	1217	1227	O
with	1228	1232	O
the	1233	1236	O
laboratory	1237	1247	O
(	1248	1249	O
Hb	1249	1251	B-Gene_or_gene_product
,	1251	1252	O
WBC	1253	1256	B-Cell
and	1257	1260	O
platelet	1261	1269	B-Cell
counts	1270	1276	O
,	1276	1277	O
and	1278	1281	O
the	1282	1285	O
percentage	1286	1296	O
of	1297	1299	O
blasts	1300	1306	O
)	1306	1307	O
and	1308	1311	O
clinical	1312	1320	O
parameters	1321	1331	O
(	1332	1333	O
organomegaly	1333	1345	O
,	1345	1346	O
duration	1347	1355	O
of	1356	1358	O
CP	1359	1361	O
,	1361	1362	O
AP	1363	1365	O
,	1365	1366	O
and	1367	1370	O
BC	1371	1373	O
)	1373	1374	O
of	1375	1377	O
disease	1378	1385	O
progression	1386	1397	O
.	1397	1398	O

RESULTS	1399	1406	O
:	1406	1407	O
The	1408	1411	O
expression	1412	1422	O
ofVEGF	1423	1429	B-Gene_or_gene_product
protein	1430	1437	O
was	1438	1441	O
most	1442	1446	O
pronounced	1447	1457	O
in	1458	1460	O
AP	1461	1463	O
(	1464	1465	O
ANOVA	1465	1470	O
,	1470	1471	O
p	1472	1473	O
=	1473	1474	O
0	1474	1475	O
.	1475	1476	O
033	1476	1479	O
)	1479	1480	O
.	1480	1481	O

The	1482	1485	O
level	1486	1491	O
of	1492	1494	O
VEGF	1495	1499	B-Gene_or_gene_product
expression	1500	1510	O
correlated	1511	1521	O
inversely	1522	1531	O
with	1532	1536	O
the	1537	1540	O
degree	1541	1547	O
of	1548	1550	O
splenomegaly	1551	1563	O
(	1564	1565	O
Pearson	1565	1572	O
,	1572	1573	O
r	1574	1575	O
=	1575	1576	O
-	1576	1577	O
0	1577	1578	O
.	1578	1579	O
400	1579	1582	O
,	1582	1583	O
p	1584	1585	O
=	1585	1586	O
0	1586	1587	O
.	1587	1588	O
011	1588	1591	O
)	1591	1592	O
.	1592	1593	O

High	1594	1598	O
expression	1599	1609	O
of	1610	1612	O
VEGF	1613	1617	B-Gene_or_gene_product
correlated	1618	1628	O
with	1629	1633	O
a	1634	1635	O
shorter	1636	1643	O
overall	1644	1651	O
survival	1652	1660	O
(	1661	1662	O
log	1662	1665	O
rank	1666	1670	O
,	1670	1671	O
p	1672	1673	O
=	1673	1674	O
0	1674	1675	O
.	1675	1676	O
042	1676	1679	O
)	1679	1680	O
.	1680	1681	O

CONCLUSION	1682	1692	O
:	1692	1693	O
Immunohistochemically	1694	1715	O
confirmed	1716	1725	O
significance	1726	1738	O
of	1739	1741	O
the	1742	1745	O
expression	1746	1756	O
of	1757	1759	O
VEGF	1760	1764	B-Gene_or_gene_product
in	1765	1767	O
dependence	1768	1778	O
of	1779	1781	O
the	1782	1785	O
CML	1786	1789	O
stage	1790	1795	O
could	1796	1801	O
be	1802	1804	O
of	1805	1807	O
clinical	1808	1816	O
importance	1817	1827	O
in	1828	1830	O
deciding	1831	1839	O
on	1840	1842	O
the	1843	1846	O
timing	1847	1853	O
therapy	1854	1861	O
.	1861	1862	O

These	1863	1868	O
data	1869	1873	O
suggest	1874	1881	O
that	1882	1886	O
VEGF	1887	1891	B-Gene_or_gene_product
plays	1892	1897	O
a	1898	1899	O
role	1900	1904	O
in	1905	1907	O
the	1908	1911	O
biology	1912	1919	O
of	1920	1922	O
CML	1923	1926	O
and	1927	1930	O
that	1931	1935	O
VEGF	1936	1940	B-Gene_or_gene_product
inhibitors	1941	1951	O
should	1952	1958	O
be	1959	1961	O
investigated	1962	1974	O
in	1975	1977	O
CML	1978	1981	O
.	1981	1982	O

